-+ 0.00%
-+ 0.00%
-+ 0.00%

Parabilis Medicines to Present Updated Zolucatetide Trial Data in Desmoid Tumors at ESMO 2026

PUBT·10/19/2026 11:08:03
Listen to the news
Parabilis Medicines to Present Updated Zolucatetide Trial Data in Desmoid Tumors at ESMO 2026
  • Parabilis Medicines will present updated zolucatetide Phase 1/2 desmoid tumor data at ESMO Congress in Madrid on October 24, 2026.
  • The presentation will cover safety and efficacy findings from dose escalation and optimization, using a June 22, 2026, data cutoff.
  • Dose optimization is designed to guide dose and schedule selection for a planned registrational Phase 3 trial.
  • Zolucatetide holds FDA Fast Track and Orphan Drug designations for desmoid tumors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Parabilis Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190700PRIMZONEFULLFEED9847619) on October 19, 2026, and is solely responsible for the information contained therein.